NLM Digital Collections

Search

Start Over Subjects Fraud ✖Remove constraint Subjects: Fraud Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

1. Questionable billing for compounded topical drugs in Medicare Part D

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Dermatologic Agents -- economics
Dermatologic Agents -- therapeutic use
Drug Compounding -- economics
Drug Utilization -- trends
Fraud
Insurance, Health, Reimbursement
Medicare Part D -- economics
Skin Cream -- economics
Administration, Topical
Dermatologic Agents -- adverse effects
Drug Compounding -- standards
Forecasting
Health Expenditures -- trends
Insurance Coverage
Skin Cream -- adverse effects
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

2. The promise of telehealth for hospitals, health systems, and their communities

Publication:
Washington, DC : American Hospital Association, January 2015
Subject(s):
Hospitals
Telemedicine -- organization & administration
Community Health Services
Computer Security
Delivery of Health Care, Integrated
Fraud
Health Services Accessibility
Insurance, Health, Reimbursement
Licensure
Medicaid
Medicare
Monitoring, Ambulatory
Privacy
Remote Sensing Technology
Rural Health Services
Telemedicine -- utilization
Humans
United States

3. State health- insurance marketplaces: three states used varied data sources for eligibility and had few indications of potentially improper enrollments : report to Congressional requesters

Publication:
Washington, D.C. : U.S. Government Accountability Office, September 2017
Subject(s):
Cost Sharing -- economics
Eligibility Determination
Health Insurance Exchanges
Insurance, Health -- economics
Fraud
Income Tax
Humans
Idaho
Maryland
Rhode Island
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)

5. Business of health insurance

Author(s):
Berry, Melissa D., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Insurance Coverage -- legislation & jurisprudence
Insurance, Health -- legislation & jurisprudence
Emigrants and Immigrants -- legislation & jurisprudence
Fraud
Health Benefit Plans, Employee
Health Care Costs
Health Facility Merger
Medicare
Politics
Preexisting Condition Coverage
State Government
Universal Health Insurance
Humans
United States
United States.

7. Opioid crisis

Author(s):
Berry, Melissa D., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Health Care Reform -- legislation & jurisprudence
Opioid-Related Disorders -- epidemiology
Opioid-Related Disorders -- therapy
Commerce
Criminal Law
Drug Industry
Federal Government
Fentanyl
Fraud
Health Services Accessibility
Internet
Inappropriate Prescribing
Liability, Legal
Naloxone
Narcotic Antagonists
Opiate Substitution Treatment
State Government
Humans
China
United States

8. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

9. Business practices

Author(s):
Steiner, David J., author
Publication:
Toronto, Ontario : Thomson Reuters, 23-December-2019
Subject(s):
Commerce
Drug Industry -- legislation & jurisprudence
Equipment and Supplies
Legislation, Drug
Analgesics, Opioid
Crime
Equipment Failure
Equipment Safety
Federal Government
Fraud
Medical Device Recalls
Opioid-Related Disorders -- epidemiology
Patents as Topic
Prescription Drug Diversion
Humans
United States

10. Wholesale distributor verification requirement for saleable returned drug product and dispenser verification requirements when investigating a suspect or illegitimate product: compliance policies : guidance for industry

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, August 2023
Subject(s):
Counterfeit Drugs
Drug Industry
Drug and Narcotic Control
Fraud
Government Regulation
Substandard Drugs
United States
United States.